

September 9-10, 2024 | Boston, MA



ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Invest, Acquire, License, Partner

Collaborate & Partner Across ADC & Radiopharmaceutical Pipelines & Platforms, to De-Risk & Differentiate, Validate Your Technologies & Raise Capital

Your 40+ Speaker Faculty Includes:



Steven Bartz
Head of Oncology
Business Development,
Search & Evaluation
Pfizer



David Dowling
Global Search &
Evaluation Lead,
Oncology Strategy
Roche



Adrienne Wong
Director, Oncology
Search & Evaluation,
Global Business
Development
Daichi Sankyo



Albert Hsia
Executive Director,
Business Development
Merck



Laura Collins
Senior Director,
Transactions, Business
Development
AstraZeneca



Andressa Smith
Senior Director,
Scientific Licensing &
Acquisition, Oncology
Business Development
Johnson & Johnson



Irene Blat
Senior Director, Search
& Evaluation
Servier Pharmaceuticals



Venky Raghavan
Executive Director
Search & Evaluation
Oncology
Novartis




Christopher Davies
Business Development
Project Leader
Genentech



Chris O'Donnell
Vice President
Business Development
Pfizer

2024 Partners:



THE HYPER-RELEVANT PARTNERSHIP EVENT DELIVERING BETTER ACCESS TO DISRUPTIVE SCIENCE, CAPITAL & DEALS, FOR ADCS & RADIOPHARMACEUTICALS

WHAT CAN YOU EXPECT?



100 + Attending companies developing innovative pipeline and platforms across ADCs, novel conjugates, and radiopharmaceuticals



20+ Hours of face-to-face networking with stakeholders across pharma, biotech, venture, intellectual property, and financial advice



16 + Company presentations showcasing new data and disruptive new technologies in early development



100% Alignment of interest to generate an unmissable number of conversations, partnerships and deals... **join us to find out!**




INVEST, ACQUIRE, LICENSE, PARTNER

Hosting an unmissable audience of 100+ ADC decision makers from 60+ companies, the **ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit** brings together on-scope and in-strategy companies to **drastically improve the hit-rate and alignment of ADC and radioligand partnership conversations**, guaranteeing other attendees are valuable prospects looking to do deals.

With a spotlight on early discovery to clinical proof-of-concept programs, this concentrated networking-led conference will echo recent deals from BMS/Orum, Roche/MediLink, and Novartis/Mariana, and provide a platform to present novel payloads, future click-release chemistry, antibody fragments offering higher DAR, and the **“what’s next” of ADC partnering, to understand the true appetite for future clinical assets.**

Whether you are a large pharma scouting earlier-stage disruptive science, an investor seeking strategic assets with viable exits to diversify portfolios, or a biotech looking to validate technologies through attractive licensing, this forum will ensure **visibility across business-to-business buy/sell ADC opportunities.**

Cut through the noise of larger events to find the right partner, faster.

-  Capitalize on protected face-to-face networking, with an audience 100% aligned on interests, to more efficiently generate opportunities with the potential for high-yield deals
-  Understand assessment criteria, data package expectations and due diligence of buyers, and hear invaluable feedback into your financing or clinical development programs
-  Evaluate the total landscape of emerging pipelines and platforms to discuss collaboration and licensing options with similar stakeholders seeking creative partnerships to accelerate assets to the clinic

Maximize the value of your technology, move your exit strategy forwards, and collaborate on new assets to propel your pipeline forwards in the biggest area for commercial growth: ADCs.

▀▀ This will be a great opportunity to focus on new developments and meeting the key players in ADCs and radiopharmaceuticals ▀▀

Adrienne Wong, Director Oncology Search & Evaluation, Global Business Development, **Daiichi Sankyo**

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



WHO IS ATTENDING TO PARTNER

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

LARGE PHARMA

Gathering oncology large pharma innovation scouts and business development teams, looking to assess, qualify, or understand due diligence on promising technologies for external innovation.

Assess disruptive science across novel linker and conjugation technologies and future payloads or radioligands, and evaluate new collaboration opportunities, earlier in development.

This face-to-face, targeted partnership opportunity is for:

- Search & Evaluation
- Licensing & Acquisitions
- Venture
- External Innovation
- Transactions
- Business Development



Andressa Smith
Senior Director, Scientific Licensing & Acquisition, Oncology Business Development
Johnson & Johnson



David Dowling
Global Search & Evaluation Lead, Oncology Strategy
Roche

“I hope to collaborate with my colleagues in the industry to discuss and brainstorm the best ways to bring forth the next generation of ADCs”
Christopher Davies, Business Development Project Leader, Genentech

BIOTECH & ACADEMICS FORMING COMPANIES

Creating a platform for face-to-face networking with targeted investment, acquisition, licensing, and partnership decision-makers, understand buying activity and strategy to align with promising collaborators.

Validate your technologies to differentiate in a competitive market, raise capital for re-investment, and expand the list of buyers interested in your promising new science.

Enabling better exposure, greater engagement, and more opportunity for constructive meetings, for:

- Chief Executive Officers
- Head of Business Development
- Chief Scientific Officers
- Founders & Co-Founders



John Flygare
Co-Founder & Chief Scientific Officer
Firefly Bio



Neil Bander
Founder & Chief Scientific Officer
Convergent Therapeutics

“This is an opportunity to meet and exchange with the whole community burning to the true potential of ADCs”
Ingo Lehrke, Chief Business Officer, Tubulis

INVESTORS & CORPORATE VENTURE

Filled with company presentations, strategic insights from deal-making activity, and direction into future trends, to help evaluate strategic assets with promising returns.

Identify attractive investment opportunities, outline your differentiated expertise, and establish a greater track record of delivering targeted capital across ADCs.

Creating opportunity to meet companies outside of existing portfolios, to expand investment footprint, for:

- Investment Directors
- Principals
- Partners
- Head of Corporate Venture



Cookie Yu
Investment Director
Samsung Venture Investment Corporation



Harris Weber
Principal
Bain Capital Life Sciences

“I’m thrilled to attend this unique meeting for its networking opportunities with innovators at the cutting edge of ADC therapy, expecting to collaborate”


Harris Webber, Principal, Bain Capital Life Sciences



PARTNERING FEATURES

CONFERENCE FORMAT & CONFIGURATION

Aligned by interests, experience, and expectations, the **ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit** concentrates on networking, presenting, and face-to-face meetings across two rooms, so you don't lose time finding the right people. Run into decision makers and key prospects, present to the whole audience to receive maximum engagement, and book private meeting spaces via the partnership portal to increase the efficiency and yield of your scheduled and spontaneous business meetings.



ONE-TO-ONE PARTNERING THROUGH THE PARTNERSHIP PORTAL

Take full advantage of the partnership portal, including the full attendee list and attendee profiles, to schedule meetings in advance, and qualify yourself as an interesting prospect.



Use payload, antibody, linker, or target-specific searches to identify in-strategy and interesting prospects ahead of time.



Advertise your exciting science or partnership interests to aligned companies by updating your attendee profile.



Set availability and schedule meetings during partnering hours to automatically populate your calendar and reserve a meeting booth.

ORGANIZED NETWORKING SESSIONS:

PHARMA MATCHMAKING ROUNDTABLES

Qualify yourself and others as valuable prospects by getting face-to-face time with the pharma faculty at the first opportunity.

Rotate through pharma tables to understand how you align with search and evaluation interests, hear in-person feedback, and introduce your ADC innovations to multiple stakeholders, all within the first few hours!

ROUNDTABLE DISCUSSIONS FOR SCIENTIFIC ALIGNMENT:

Join roundtables of companies across the novel linker and conjugation technologies, future payloads, radiopharmaceuticals, and emerging conjugate formats to evaluate how exciting new science can revolutionize existing target opportunities, de-risk the need to differentiate and move towards success in expanded indications.



YOUR 40+ SPEAKER FACULTY



Adrienne Wong
Director, Oncology
Search & Evaluation,
Global Business
Development
Daiichi Sankyo



Akihiro Furukawa
Director Research &
Technology Search
& Evaluation
Global Business
Development
Daiichi Sankyo



Albert Hsia
Executive
Director, Business
Development
Merck



Andressa Smith
Senior Director,
Scientific Licensing
& Acquisition,
Oncology Business
Development
Johnson & Johnson



Avnish Kapoor
Vice President,
Head of Business
Development
Systemimmune



Bob Lutz
Chief Scientific
Officer
Iksuda Therapeutics



Carlos Loya
Venture Partner
82VS



Christopher Davies
Business
Development
Project Leader
Genentech



Chris O'Donnell
Vice President
Business
Development
Pfizer



Cookie Yu
Investment Director
Samsung Venture
Investment
Corporation



Cynthia Li
Vice President
Business
Development
CytomX
Therapeutics



Daniel Calarese
Senior Director,
Innovation &
Strategy
Sutro Biopharma



David Dowling
Global Search &
Evaluation Lead,
Oncology Strategy
Roche



Doo Young Jung
Chief Executive
Officer
Pinotbio



Filippo Mulinacci
Chief Business
Officer
Aranis Biotech



Giorgio Salciarini
Head of Sales -
Technical Business
Development
BSP
Pharmaceuticals



Greg Dwyer
Vice President,
Head of Business
Development
Orum Therapeutics



Gwenn Hansen
Chief Scientific
Officer
Nurix Therapeutics



Harris Weber
Principal
Bain Capital Life
Sciences



Irene Blat
Senior Director,
Search & Evaluation
Servier
Pharmaceuticals



Ingo Lehrke
Chief Business
Officer
Tubulis



Isan Chen
Co-founder,
President & Chief
Executive Officer
Mbrace
Therapeutics



Jake Morris
Senior Account
Manager
Beacon by Hanson
Wade



Joey Xiao
Co-founder & Chief
Operating Officer
MediLink
Therapeutics

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE





Kalyan Chakravarthy
Associate Director,
External Innovation
Ipsen



Kamran Ali
Co-Founder & Chief
Technology Officer
Eigen



Kilang Yanger
Associate
Director, Business
Development
Search & Evaluation
BMS



Laura Collins
Senior Director,
Transactions,
Business
Development
AstraZeneca



Liat Izhak
Director, Search &
Evaluation, Business
Development
Genmab



Marc Robillard
Chief Executive
Officer & Founder
**Tagworks
Pharmaceuticals**

WELCOME



Masashi Shimazaki
Senior Director
- Primary Focus
Area Targeted
Protein Degradation,
Portfolio Strategy
Lead
Astellas Pharma



Matthew Atkey
Partner
Mintz



Melissa Conner
Senior Director
of Business
Development,
Acquisitions &
Licensing
**Janssen
Pharmaceuticals**



Natalia Ulyanova
Business
Development
Director, Oncology
Astellas Pharma



Neil Bander
Founder, Chief
Scientific Officer
**Convergent
Therapeutics**



Owen Dempsey
Chief Executive
Officer
Avipep Therapeutics

EXPERT SPEAKERS



**Patrick Zweidler-
McKay**
Executive Medical
Director
AbbVie



Qing Zhou
Founder & Chief
Executive Officer
Escugen



Sophie Brachet
Head of Early
Commercial &
Access
**Debiopham
International**



Steve Bartz
Head of Oncology
Business
Development,
Search & Evaluation
Pfizer



Travis Biechele
Vice President &
Head of Research
Shasqi



Venky Raghavan
Executive Director
Search & Evaluation
Oncology
Novartis

AGENDA

“I am excited to join this targeted meeting to meet and network with many like-minded companies and individuals in the field of ADC, as we look forwards to bring innovative technologies and ideas to improve ADCs for cancer patients”

Andressa Smith, Senior Director Scientific Licensing & Acquisition, Oncology Business Development, **Johnson & Johnson**

“I see this as a great opportunity to network with industry peers and charter new exciting paths for the recently revived ADC field”

Natalia Ulyanova, Business Development Director, Oncology, **Astellas Pharma**

PARTNER WITH US

REGISTER YOUR PLACE



6



+1 617 455 4188



info@hansonwade.com



www.adc-partnering.com



hansonwade

PART ONE: FIND YOUR FUTURE PARTNER

Bringing you a targeted and hyper-relevant partnership opportunity from the start, this opening section brings key buyers together in a unique and unmissable format, to find you your next partner and route to more capital.

8.00-9.00		Activity in ADCs, Appetite for Radioligands & Alignment for Business from the Pharma Icebreaker
10.15 - 12.15		Face-to-face protected networking time during the Search & Evaluation Roundtables to qualify, hear feedback, and generate interest for the rest of the conference.

Bob Lutz
Chief Scientific Officer **7.45** **Chairs Opening Remarks**
Iksuda Therapeutics

Strategic Priorities & Deal Trends for Future Collaborations & Investment in ADC & Radioligands

8.00 **Pharma Icebreaker: Activity in ADCs, Appetite for Radioligands & Alignment for Business**

• Discussing recent deal-making and current search and evaluation interests for context in the conference to follow

Adrienne Wong
Director, Oncology Search & Evaluation, Global Business Development
Daichi Sankyo

Natalia Ulyanova
Business Development Director, Oncology
Astellas Pharma

Kilang Yanger
Associate Director, Business Development Search & Evaluation
BMS

Christopher Davies
Senior Manager, Business Development
Genentech

Kalyan Chakravarthy
Associate Director, External Innovation
IpSen

Andressa Smith
Senior Director, Scientific Licensing & Acquisition, Oncology Business Development
Johnson & Johnson

Albert Hsia
Executive Director, Business Development
Merck

Venky Raghavan
Executive Director Search & Evaluation Oncology
Novartis

Steve Bartz
Head of Oncology Business Development, Search & Evaluation
Pfizer

Liat Izhak
Director, Search & Evaluation, Business Development
Genmab

Irene Blat
Senior Director, Search & Evaluation
Servier Pharmaceuticals

Andy Hass
Associate Vice President, Oncology Search & Evaluation
Eli Lilly

9.00 **Short Comfort Break to Arrange Matchmaking Tables**

9.15 **Pharma Matchmaking Roundtables**

Rotate through pharma tables to understand how you align with search and evaluation interests, hear in-person feedback, and introduce your ADC innovations to multiple stakeholders.

Select your tables ahead of time, and attend four 30-minute meetings across 2 hours of protected networking time.



Adrienne Wong, Director, Oncology Search & Evaluation, Global Business Development

Akihiro Furukawa, Director Research & Technology Search & Evaluation Global Business Development



Natalia Ulyanova, Business Development Director, Oncology

Masashi Shimazaki, Senior Director Targeted Protein Degradation, Portfolio Strategy Lead




Christopher Davies, Senior Manager, Business Development

David Dowling, Global Search & Evaluation Lead, Oncology Strategy



Andressa Smith, Senior Director, Scientific Licensing & Acquisition, Oncology Business Development

Melissa Conner, Senior Director of Business Development, Acquisitions & Licensing



Kilang Yanger, Associate Director, Business Development Search & Evaluation



Kalyan Chakravarthy, Associate Director, External Innovation



Venky Raghavan, Executive Director Search & Evaluation Oncology



Steve Bartz, Head of Oncology Business Development, Search & Evaluation



Liat Izhak, Director, Search & Evaluation, Business Development



Irene Blat, Senior Director, Search & Evaluation



Andy Hass, Associate Vice President, Oncology Search & Evaluation

11.30 Lunch Break & Networking

PART TWO: SHOWCASE YOUR SCIENCE

Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to showcase your pipeline, platform, and technologies to a room of aligned and qualified decision-makers.

Bringing Clarity to the Deal Frenzy: Clinical Progress & Capital Invested In The Last 12 Months

1.10 Venture Panel: Differences in Venture Across Investors

- Sharing relevant investments to date across ADC and radiopharmaceutical portfolios to evaluate specific venture interests and expertise
- Discussing desirable science to add to portfolios and how companies can position themselves for investment in this competitive market
- Drawing upon examples of significant series funding and investment to suggest new trends in exciting science



Cookie Yu
Investment Director
**Samsung Venture
Investment Corporation**



Carlos Loya
Venture Partner
82 VS



Harris Weber
Principal
**Bain Capital Life
Sciences**



Chris O'Donnell
Vice President Business
Development
Pfizer

Radiopharmaceuticals & Novel Antibody Formats: Marrying Novel ADC Formats with Radioisotopes to Improve Tumor Selectivity & Create Exciting Therapeutic Potential



Neil Bander
Founder, Chief
Scientific Officer
**Convergent
Therapeutics**

1.40 The Radiopharmaceutical Fork in the Road: Radioantibodies versus Radioligands

- Does the success of Lutathera and Pluvicto foretell a wave of effective Radioligands
- Paradoxical advantages/disadvantages of ligands and antibodies
- Blending Radioantibodies and Radioligands: the ideal Radiopharmaceutical approach



Bob Lutz
Chief Scientific Officer
Iksuda Therapeutics
(Advisor to **Avipep
Therapeutics**,
presenting on their
behalf)

2.00 AvDCs (Avibody Drug Conjugates): A Targeted Approach to Efficacy, Improved Tolerability & Favorable PK for Targeted Radio-Therapy, Novel ADC Formats, & Enhanced Tumor Selectivity

- Avibodies are engineered, bivalent mAb fragments, precisely loaded with radiotoxic or cytotoxic payloads
- Sharing pre-clinical data demonstrating traditional ADC, novel pre-targeting, and targeted radio therapy formats
- Biparatopic or bispecific designs against TSEs (Tumor Specific Epitopes) can further enhance solid tumor selectivity









Giorgio Salciarini
Head of Sales -
Technical Business
Development
BSP Pharmaceuticals

2.20 A Step Ahead Against the Challenges of the Bioconjugates

- Discover the insides of a sustainable business model
- Learn about expertise, technology and integration of services
- Discuss capacity shortage challenges: what it means going forward


2.40 Afternoon Break & Networking

Conjugation & Click Release Chemistry: Stability, Solubility & Tumor Specificity

 Sophie Brachet Head of Early Commercial & Access Debiopharm International	3.40	Why Are ADCs a Strategic Pillar at Debiopharma? <ul style="list-style-type: none">• Debiopharm's perspectives on why we believe ADCs are hot• Our approach to add value for out-licensing partners
 Marc Robillard Chief Executive Officer & Founder Tagworks Pharmaceuticals	4.00	Click-Cleavable ADCs <ul style="list-style-type: none">• Expanding the therapeutic window and application scope of ADCs through <i>in vivo</i> click release chemistry, to increase efficacy and decrease toxicity• Updates on TGW101, targeting TAG72, inaccessible with current ADC technologies• Insights to radiotherapeutics programs to date
 Cynthia Li Vice President Business Development CytomX Therapeutics	4.20	PROBODY® Conditional Activation Technology Designed to Expand ADC Target Landscape <ul style="list-style-type: none">• Sharing industry-leading PROBODY® masking technology which leverages elevated protease activity in the tumor microenvironment and is designed to increase the therapeutic index by reducing on-target off-tumor toxicities while potentially maintaining potent anti-tumor efficacy.• Discussing PROBODY® platform with proof of mechanism: stability in circulation, intratumoral activation and single agent activity across multiple indications.• Outlining how PROBODY® technology is designed to unlock EpCAM as a systemic ADC target (CX-2051, PROBODY® EpCAM-Topo1 ADC currently in Ph1) and may be applied to other ADC targets with low or negative therapeutic index
 Ingo Lehrke Chief Business Officer Tubulis	4.40	Tubulis – Reimagining ADCs From Concept to Clinics <ul style="list-style-type: none">• Expanding the therapeutic potential of protein-drug conjugate through increased design flexibility, leveraging the right platform to create ADCs with superior biophysical properties• Updates on Tubulis' proprietary programs• Seeking new conjugates to fill Tubulis' pipeline and collaborations for the new era of ADCs
 Travis Biechele Vice President & Head of Research Shasqi	5.00	Developing Next-generation Targeted Therapies using Click Chemistry <ul style="list-style-type: none">• Introducing Shasqi's Click Activated Protodrugs Against Cancer (CAPAC), how it overcomes the major limitation of ADC and RLT approaches by separating tumor antigen binders from payloads, reuniting them at the tumor via click chemistry• Discussing CAPAC design heuristics and methods that inform therapeutic design• Updates on Shasqi's proprietary programs
 Bob Lutz Chief Scientific Officer Iksuda Therapeutics	5.20	Chair's Closing Remarks

5.20 Drinks Reception & Informal Networking:

"People work with people". Catch up with the field in Boston, and candidly network during the ADC & Radiopharmaceuticals Pharma & Biotech Partnering Drinks Reception, to initiate and reinforce existing business relationships built before or during the conference so far.



SHOWCASE YOUR SCIENCE CONTINUED



Patrick Zweidler-McKay
AbbVie

7.40 **Chairs Opening Remarks**



Patrick Zweidler-McKay
AbbVie

7.45 **The ADC Dream: Why ADCs are More Alive Than Ever**

- Answering the question, what is the dream for ADCs?
- Evaluating and learning from the journey for ADCs to hit their stride
- Outlining why ADCs are now seeing success and what the future holds

What's the Next Payload? Developing a Differentiated ADC for Future First-in-Line Therapeutic Options

8.15 **Panel Discussion: DACs, Protacs & Molecular Glues: Why is ADC Technology What Protein Degradation Needs?**

- Discussing mechanistic differences across protein degradation payloads, their therapeutic role, and liabilities
- Demonstrating a protein degradation therapeutic window, and selective delivery with antibodies
- Understanding why protein degradation experts believe ADC technology is needed



Greg Dwyer
Vice President, Head Business Development
Orum Therapeutics



Gwenn Hansen
Chief Scientific Officer
Nurix Therapeutics



Ingo Lehrke
Chief Business Officer
Tubulis



Greg Dwyer
Vice President, Head Business Development
Orum Therapeutics

8.45 **TPD²: Cell Selective Degradation**

- Improving upon efficacy, safety, and half-life of conventional targeted protein degraders
- Orum's proprietary Dual-precision Targeted Protein Degradation (TPD²™) approach uses antibodies to precisely deliver small molecule targeted protein degrader payloads to cancer cells
- Discussing collaboration possibilities across TPD² and TPS² platforms and programs



Gwenn Hansen
Chief Scientific Officer
Nurix Therapeutics

9.05 **Tumor-Specific Delivery of Potent Degraders**

- Introducing Nurix' expertise in DELigase, targeted protein modulation, targeted protein degradation, targeted protein elevation, and degrader-antibody conjugates
- Targeting degraders to the CNS for the treatment of cancer
- Discussing collaborations

9.25 **Morning Break & Networking**



Filippo Mulinacci
Chief Business Officer
Araris Biotech

10.00 **Multi-Warhead ADCs Assembled in One-Step Without Antibody Engineering**

- Traditional chemotherapy remains a cornerstone in treating various cancers, typically involving combinations of multiple cytotoxic agents
- Dual- and triple-warhead ADCs offer a breakthrough by enhancing chemotherapy combinations with precise targeting, significantly expanding the therapeutic window and improving outcomes
- Araris AraLinQ™ technology enables the one-step creation of stable, highly potent ADCs with diverse payloads, designed to overcome tumor resistance and heterogeneity while minimizing toxicity

Revisiting & Discovering New Target Opportunities to Expand ADC & Radioligand Delivery



Kamran Ali
Co-Founder & Chief Technology Officer
Eigen

10.20 **Development of a Priming Approach to Enhance Antigen-directed Therapies in Hematological Malignancies & Solid Tumors**

- Session details to be released



Isan Chen
Co-founder, President &
Chief Executive Officer
Mbrace Therapeutics

10.40 Mbrace Therapeutics: Developing Novel Targets & Antibodies using SPARTA

- SPARTA is a phage-based library of human antibodies
- This antibody library can be used for discovery of new antibody/target pairs
- SPARTA

11.00 Roundtable Discussions for Scientific Alignment:

Join roundtables of companies across novel linker and conjugation technologies, future payloads, and radioligands; or groups identifying new targets in expanded tumor types, to discuss how exciting new science can revolutionize existing or open up new targets.

CHEMISTRY TABLE

Can we Succeed by Applying New Technology to Known Targets?

- Debating the notion of known ADC targets seeing a change in success with the new linker payload format
- Discussing the industry's sentiment on a second look, with more stable conjugation and release chemistry that takes advantage of different enzymes and payloads
- Judging the potential therapeutic window of phase 1 by comparing preclinical data of new and historical studies

BIOLOGY TABLE

How Do You Make a "Cold Tumor", Hot?

- Comparing hot and cold tumors in the context of ADCs, including known examples to evaluate the most promising market opportunities for ADC
- Discussing factors of a tumor that lead to response as hot versus cold to further the field's understanding
- Evaluating opportunity and means to turn a cold tumor hot, to improve response to ADCs, including immune-based combination therapy



Doo Young Jung
Chief Executive Officer
Pinotbio

11.30 Novel Antibody-Drug Conjugates (ADCs) with Dual Payloads – Pinot-AD₂C

- Successfully providing novel Top1i payloads and super-hydrophilic linkers to ADC development partners
- Achieving better therapeutic window, we created a novel dual payload ADC platform, Pinot-AD₂C, comprising 2 payloads with independent MoAs
- Employing Top1 inhibitor payload and other conventional ultrapotent payloads in an optimized ratio to show improved efficacy profiles than those of conventional Top1i ADCs, while maintaining good safety profile of Top1i based ADCs
- Discussing potential collaborations for Pinot-AD₂Cs and, also for Pinotbio's unique Top1i payload and super-hydrophilic linker



Qing Zhou
Founder & Chief
Executive Officer
Escugen

11.50 EZWi-Fit[®], A Novel ADC Platform Technology with Improved Efficacy & Safety

- EZWi-Fit[®] employs Top1 inhibitor as the payload with intrinsic potency higher than Dxd. The payload is not the substrate of ABC transporter, and has remarkable by-stander effect.
- The chemically modified stable cleavable linker is high hydrophilic. With non-MC chemical conjugation, the de-conjugation of the linker-payload is largely reduced.
- ADC derived from EZWi-Fit[®] platform exhibits in vivo efficacy superior to that of GGFG-Dxd ADC, regardless of the targets and tumor types. The ADCs demonstrate tumor suppression or eradication activity on multiple CDX and PDX models that were resistant to MMAE or Dxd. The ADCs also demonstrate impressive activity even when the target expression is low.
- With low clearance, EZWi-Fit[®] derived ADC has great serum and tumor exposure. NHP Safety evaluations on multiple EZWi-Fit[®] derived ADC demonstrate great tolerance.

12.10 Lunch & Networking

Creative Partnerships & Deal Processes: How to Differentiate in the Buy/Sell Dynamic



Jake Morris
Senior Account
Manager
**Beacon by Hanson
Wade**

1.20 Clinical Data, Deals & Company Analysis Across the ADCs & Radiopharmaceuticals

- Summarizing clinical and partnership developments to track the increasingly global ADC landscape
- Understanding venture investment to evaluate the potential of early discovery and preclinical science
- Reviewing the direction of global partnerships, specifically why there are so many deals being done with Asia

DAY TWO

SEPTEMBER 10, 2024

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

1.40 Effectively & Efficiently Structuring Deal Processes as a Small ADC or Radiopharmaceutical Company

- Discussing the panel's experiences executing and performing due diligence for noteworthy ADC and radiopharma, mergers, and licensing deals
- Sharing pharma's expectation for data packages and deal process; how to differentiate in the buy/sell dynamic
- Outlining creative partnerships and deal structures that create effective BD&L in 2024



Avnish Kapoor
Vice President,
Head of Business
Development
Systemmune



Greg Dwyer
Vice President,
Head Business
Development
**Orum
Therapeutics**



**Filippo
Mulinacci**
Chief Business
Officer
Araris Biotech



Laura Collins
Senior Director,
Transactions,
Business
Development
AstraZeneca



**Matthew
Atkey**
Partner
Mintz



Daniel Calarese
Senior Director,
Innovation & Strategy
Sutro Biopharma

2.10 Therapeutic Index Improvements of ADCs: What Are the Next Breakthroughs?

- Discussing the impact of ADC design on anti-tumor activity and platform adverse events
- Clinical liabilities of Exatecan/Top1 based ADCs and mitigation strategies
- Dual payload conjugates: same or better than chemo combos?



Joey Xiao
Co-founder & Chief
Operating Officer
MediLink Therapeutics

2.30 MediLink Corporate Presentation

- Sharing a company overview
- Introducing the TMALIN® ADC platform
- Sharing MediLink's partnering strategy

2.50 Chair's Closing Remarks

3.00 Conference "In Session" Agenda Finished

Coffee Refreshed & Partnering in One-on-One Portal Still Available for Meeting Scheduling

▀▀ I look forward to connecting with our biotech/pharma peers who are the forefront of advancing innovation in this field ▀▀

Avnish Kapoor, Vice President, Head of Business Development, Systemmune

▀▀ Bringing biotech and large pharma together to spur innovation in the blossoming ADC field is the best way to advance the best science, multiply opportunities, and assure ADCs live up to the Dream! ▀▀

Patrick Zweidler-McKay, Executive Medical Director, AbbVie



2024 EVENT PARTNERS

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Expertise Partner

BSP Pharmaceuticals is a Contract Development and Manufacturing Organization fully dedicated to antineoplastic drugs, designed to handle the complexity of biopharmaceutical products and offering customized services to support its client from development to commercial manufacturing of injectables and oral formulations. BSP Pharmaceuticals is focused on innovative therapies such as Proteosome Inhibitors, Antibody Drug Conjugates (ADCs), Liposomal formulations, handling the major platforms of ADC compounds currently in clinical and commercial phase.

www.bsppharmaceuticals.com



Panel Partner

Mintz is a leading 600+ attorney law firm with deep experience in the life sciences industry. We help entrepreneurs launch and protect great ideas, facilitate funding opportunities, work with leading industry investors and underwriters in innovative financings and offerings, represent strategics, private equity firms, venture-backed businesses and entrepreneurs in buy- and sell-side M&A transactions, and counsel emerging as well as established and public companies in all aspects of their businesses, including intellectual property matters and regulatory approvals and compliance.

www.mintz.com



Pipeline Innovation Partner

AVIPEP Therapeutics is a next-generation ADC company developing a pipeline of AvDCs (Avibody Drug Conjugates) with a focus on improved tumor targeting to deliver best-in-class clinical results and to better fight relapsed/refractory disease. Privately-held and based in Cambridge MA and Melbourne VIC, AVIPEP is eager to discuss co-development, asset out-licensing or investment. Our proprietary Avibody™ platform will improve targeting and tolerability in all manner of next-gen ADCs.

www.avipep.com



Pipeline Innovation Partner

Debiopharm is an innovation-focused, Swiss biopharmaceutical company that aims to develop innovative therapies to target high unmet medical needs in oncology and infection diseases. We establish partnerships with academic, biotech, and pharmaceutical institutions to bridge the gap between disruptive discovery products and international patient reach. Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential including a CD37-targeted ADC for AML/MDS (Debio 1562M) and a HER3-targeted ADC in solid tumors (Debio 0532).

www.debiopharm.com



Pipeline Innovation Partner

Eigen aims to overcome the problem of tumor heterogeneity by modulating target expression to increase the efficacy and expand the therapeutic window of antigen-directed therapies (ADC, RLT). Eigen has built a platform to identify priming therapies, which upregulate antigen expression, and can be combined with antigen-directed therapies to improve patient responses, reduce ADC/RLT toxicity, and expand the responsive patient population. Eigen is actively developing priming agents for antigen targets in oncology.

www.eigentx.com



Pipeline Innovation Partner

CytomX Therapeutics leverages its industry leading PROBODY® conditional activation masking technology to pioneer a novel class of biologics and develop a multi-modality clinical pipeline including ADCs. CX-2051, being studied in Phase 1, is a conditionally activated ADC directed toward EpCAM, a validated target with narrow therapeutic index in conventional antibody approaches. The Probody® platform is intended to unlock EpCAM as an ADC target and demonstrate the potential to significantly expand the ADC target landscape.

www.cytomx.com



Pipeline Innovation Partner

PINOTBIO develops novel treatments for patients resistant to existing therapies, focusing on antibody-drug conjugates (ADC). Utilizing robust R&D, we created the PINOT-ADC™ platform independently. Our PINOT-payload, a unique Top1 inhibitor, offers dual mechanisms of action, while the PINOT-linker reduces normal tissue absorption and toxicity risks, common challenges in ADC development. Collaborating with partners, we leverage PINOT-ADC™ technology to advance new ADC-based anticancer treatments.

www.pinotbio.com





Pipeline Innovation Partner

Shasqi's mission is to transform cancer treatment using click chemistry (Nobel-Prize winning technology) in humans. Our Click Activated Protodrugs Against Cancer (CAPAC) approach separates tumor antigen binders from payloads, reuniting them at the tumor via click chemistry. This enables oncology therapies to be present only where they are needed, maximizing efficacy by minimizing efficacy-limiting toxicities. CAPAC is clinically validated and we are advancing novel ADC & RLT therapies based on validated and new antigen targets.

www.shasqi.com



Pipeline Innovation Partner

Escugen is a clinical-stage biotech company in Shanghai, China, focusing on the development of innovative ADCs, with its most advanced project (ESG401, an innovative Trop-2 ADC) in the PhIII clinical trials. EZWi-Fit®, Escugen's proprietary linker-toxin family represents the State-of-the-Art ADC platform technology. With this technology, Escugen has established ADC pipelines against novel targets or validated targets with significant competition advantages. The platform technology has been licensed by multiple pharmaceuticals and biotech companies. Escugen is seeking opportunities for collaboration and partnership.



Branding Partner

NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical company at the forefront of advancing patient care by utilizing novel technologies to produce commercial-scale radioisotopes that, once attached to a molecule, have the ability to detect and treat cancer and other serious diseases. NorthStar routinely produces copper-67 (Cu-67) and is poised to be the first commercial-scale producer of non-carrier-added (n.c.a.) actinium-225 (Ac-225). NorthStar's Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs.

www.northstarm.com



Branding Partner

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years' experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services. Sterling has six facilities across the UK, USA and Europe, employing 1,350+ people.

www.sterlingpharmasolutions.com


PRESENT & FIND THE RIGHT PARTNER

Gathering Chief Business Officers, VPs of BD, and CEOs from over 60 companies, for 1-to-1 networking across payload, linker, antibody and target selection pipelines, this unique forum lays enabled partnering on top of scientific strategy.

Scientific Partnering Events: Creating a targeted critical mass of business decision makers and scientific leads, enabling pharma to develop external innovation strategies and 100% alignment of research between biotech looking for partnerships

Large Partnering Events:

Large-scale and diverse audiences for a high volume of enabled networking, exclusively appealing to business gate-keepers, with discussions focused on deal-making or investment.



Niche Scientific Events

like Hanson Wade Scientific Summits: Hosting smaller, specialized groups of researchers to overcome targeted drug development challenges and discuss innovations to advance research within niche areas

READY TO RISE TO THE TOP OF LIFE SCIENCE'S HOTTEST SPACE FOR INNOVATION?

Capitalize on this unmissable business development opportunity, and the most relevant gathering of ADC and radiopharmaceutical companies looking to do deals.

Get in touch at: sponsor@hansonwade.com >



Matt Ashman
Commercial Manager
Hanson Wade

READY TO REGISTER?

3 EASY WAYS TO BOOK

 www.adc-partnering.com/take-part/register

 **US** +1 617 455 4188 **EU** +44 (0)20 3141 8700

 info@hansonwade.com

Biotech, Pharma & Investors	Standard Rate Register by Sunday, September 8	On the Door Price
Two Day Attendance & Access to Partnering Portal	\$2,899 (Save \$100)	\$2,999
Academics*	Standard Rate Register by Sunday, September 8	On the Door Price
Two Day Attendance & Access to Partnering Portal	\$2,299 (Save \$100)	\$2,399
Service Provider	Standard Rate Register by Sunday, September 8	
Two Day Attendance & Access to Partnering Portal	Attendance no longer available, capacity reached	

* To qualify for academic rate you must have a current paid affiliation with a research institute. Start ups/spin outs still associated with a research institute are welcome.

If you are a CRO, CDMO or other drug research or manufacturing service provider please let us know at sponsor@hansonwade.com for partnership opportunities. If you are a law firm, investment bank or financial service, please let us know at sponsor@hansonwade.com for partnership opportunities

Team Discounts**

- 10% discount – 3 passes
- 15% discount – 4 passes
- 20% discount – 5+ passes

**Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

VENUE

Revere Hotel Boston Common
200 Stuart St, Boston, MA 02116
United States
www.reverehotel.com

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy. Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Hanson Wade Ltd, Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH, United Kingdom

 +1 617 455 4188

 info@hansonwade.com

 www.adc-partnering.com

 hansonwade

WELCOME

EXPERT SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE